NLS Pharmaceutics Aktie 138405397 / CH1384053976
2.42
USD
0.33
USD
15.79%
08.01.2025
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
NLS Pharmaceutics Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | NLS Pharmaceutics AG | 0.00 | 0.00 | USD |
| 2022 | NLS Pharmaceutics AG | 0.00 | 0.00 | USD |
| 2021 | NLS Pharmaceutics AG | 0.00 | 0.00 | USD |
| 2020 | NLS Pharmaceutics AG | - | - | USD |
| 2019 | NLS Pharmaceutics AG | - | - | USD |
| 2018 | NLS Pharmaceutics AG | - | - | USD |
Zu diesem Datensatz liegen uns leider keine Daten vor.
NLS Pharmaceutics AG Termine
| Unternehmen | Event | Datum |
|---|
NLS Pharmaceutics AG vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Hauptversammlung | Annual General Meeting | 30.06.2023 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Armistice Capital LLC | 93.47 |
| Freefloat | 65.91 |
| Ronald Hafner, MBA | 12.48 |
| J. Goldman & Co. LP | 10.30 |
| Alpha Capital Anstalt | 9.99 |
| Affinity Asset Advisors LLC | 8.11 |
| BVF, Inc. | 5.81 |
| Citadel Securities GP LLC | 5.51 |
| Armistice Capital LLC | 5.24 |
| Felix Grisard, PhD | 4.34 |
| Magnetic Rock Investment AG | 2.88 |
| Wells Fargo Clearing Services LLC | 2.29 |
| Jane Street Group LLC | 1.77 |
| Alexander C. Zwyer, EMBA | 1.62 |
| Two Sigma Securities LLC | 1.50 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 4 | 4 | 6 | 6 | 2 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Bilanz (in Mio. USD) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 0 | 0 | 0 | 6 | 9 |
| Summe Anlagevermögen | 0 | 0 | 1 | 0 | 0 |
| Summe Aktiva | 0 | 1 | 1 | 6 | 9 |
Bilanz (in Mio. USD) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 9 | 7 | 10 | 5 | 6 |
| Summe Eigenkapital | -9 | -6 | -9 | 1 | 3 |
| Summe Passiva | 0 | 1 | 1 | 6 | 9 |
Adresse
| The Circle 6, 8058 Zurich | |
| Telefon | +41 (44) 512-21-50 |
| URL | http://www.nlspharma.com |
Management
|
Alexander C. Zwyer
Chief Executive Officer & Director |
|
Audrey E. Greenberg
Independent Director |
|
Claudio L. A. Bassetti
Independent Director |
|
Eric Konofal
Chief Scientific Officer |
|
Florence Allouche Aknin
Independent Director |
|
George Apostol
Chief Medical Officer & Head-Global Research |
|
Gian-Marco Rinaldi Diaz de la Cruz
Independent Director |
|
Hervé Girsault
Head-Business Development |
|
Marianne Lambertson
Investor Relations & Media Contact |
|
Nicole Fernandez-McGovern
Chief Operating & Financial Officer |
|
Ronald Hafner
Chairman |